Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



AMSBIO: Safeguarding Organoids Through Lockdown

AMSBIO reports how the internationally renowned Hans Clevers Lab at the Hubrecht Institute, Netherlands used their CELLBANKER® reagent when they needed to freeze down their organoids at short notice ahead of the COVID-19 spring lockdown.

Read the rest of entry »

Arecor’s Partner Inhibrx Exercises Its Option To License A New Formulation Developed By Arecor In Accordance With The Terms Of Formulation Development Agreement

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.   This is the first license under a multi-product development agreement between Inhibrx and Arecor.

Read the rest of entry »

Birmingham spinout Revitope Oncology Inc announces $10m investment

University of Birmingham spinout Revitope Oncology Inc has announced a $10m investment from leading Chinese biopharmaceutical company Junshi Biosciences.

Read the rest of entry »

AMSBIO: Novel Cell Therapy for Liver Cirrhosis

AMSBIO has published an interview with researchers at Yamaguchi University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Japan, that covers their groundbreaking work to develop cell regeneration therapies for liver cirrhosis.

Read the rest of entry »

Arecor Announces Publication Of Phase I Data For AT247 In Diabetes Care

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

Read the rest of entry »

BIOCITY: Hot flushes may become a thing of the past, as Astinno wins East Midlands AHSN Accelerator

On 25 November, five pioneering life science start-ups pitched to a panel of investors as they completed the final part of their journey on the East Midlands AHSN Accelerator, delivered by BioCity.

Read the rest of entry »

Arecor: First Patient Dosed in Phase I Clinical Trial of Ultra-concentrated Rapid Acting Insulin Candidate, at 278, for Diabetes

Arecor Limited , the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278. 

Read the rest of entry »

Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies

Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, announces its expansion and move to the new Bellhouse Building at The Oxford Science Park.

Read the rest of entry »

Milton Park refreshes brand identity for a changing world and 2040 Vision

Milton Park in Oxfordshire, one of Europe’s largest science and technology communities, has refreshed its brand values and identity to reflect the way in which the world has changed in 2020 and enable it to continue to communicate its 2040 Vision, its pioneering masterplan for how the Park will sustainably grow from 9,000 people to 20,000 people.

Read the rest of entry »

University of Birmingham Enterprise: Spinout 4D Biomaterials ramps up commercialisation for 3D tissue scaffolds

2 December, 20204D Biomaterials has been awarded funding by Innovate UK for the development and commercialisation of a new class of liquid resins that can be custom-printed into bioresorbable 3D tissue scaffolds providing accelerated and improved wound healing following major surgery. 

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.